6533b828fe1ef96bd128792f
RESEARCH PRODUCT
Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemiology, biofilm production, antifungal agents consumption and drug-susceptibility
Anna Sara NavazioGiammarco RaponiEnrica Maria ProliAlessandro GiulianiGuido AntonelliAlessandra GiordanoGrazia Brunettisubject
0301 basic medicineAntifungal AgentsTime FactorsAntifungal drugYeast and Fungal ModelsPathology and Laboratory Medicinelaw.inventionHospitals Universitychemistry.chemical_compound0302 clinical medicinelawAmphotericin BMedicine and Health Sciences030212 general & internal medicineAmphotericinFluconazoleCandidaFungal PathogensPrincipal Component AnalysisMultidisciplinaryAntimicrobialsQCandidiasisREukaryotaDrugsIntensive care unitHospitalsCorpus albicansIntensive Care UnitsExperimental Organism SystemsItalyMedical MicrobiologyEngineering and TechnologyMedicinePathogensResearch ArticleBiotechnologymedicine.drugCandida Candida bloodstream infection biofilm antifungal agents drug susceptibilityCathetersScience030106 microbiologyBioengineeringMycologyMicrobial Sensitivity TestsResearch and Analysis MethodsMicrobiologyMicrobiology03 medical and health sciencesMicrobial ControlmedicineCandida AlbicansHumansMicrobial PathogensRetrospective StudiesPharmacologyVoriconazoleAntifungalsbusiness.industryOrganismsFungiBiofilmBiology and Life SciencesYeastHealth CarechemistryHealth Care FacilitiesBiofilmsAnimal StudiesMedical Devices and EquipmentAntimicrobial ResistanceCaspofunginbusinessFluconazoledescription
Candida bloodstream infection (BSI) represents a growing infective problem frequently associated to biofilm production due to the utilization of intravascular devices. Candida species distribution (n = 612 strains), their biofilm production and hospital antifungal drug consumption were evaluated in different wards of a tertiary care academic hospital in Italy during the years 2011–2016. In the considered time window, an increasing number of Candida BSI (p = 0.005) and of biofilm producing strains were observed (p<0.0001). Although C. albicans was the species more frequently isolated in BSI with a major biofilm production, an increased involvement of non-albicans species was reported, particularly of C. parapsilosis that displayed a high frequency in catheter infections, and lower biofilm production compared to C. albicans. Although trends of biofilm production were substantially stable in time, a decreasing biofilm production by C. parapsilosis in the Intensive Care Unit (ICU) was observed (p = 0.0041). Principal component analysis displayed a change in antifungal drugs consumption driven by two mutually independent temporal trends, i.e. voriconazole use in the general medicine wards initially, and fluconazole use mainly in the ICU; these factors explain 68.9% and 25.7% of total variance respectively. Moreover, a significant trend (p = 0.003) in fluconazole use during the whole time period considered emerged, particularly in the ICU (p = 0.017), but also in the general medicine wards (p = 0.03). These trends paralleled with significant increase MIC90 of fluconazole (p = 0.05), particularly for C. parapsilosis in the ICU (p = 0.04), with a general and significant decreased trend of the MIC90 values of caspofungin (p = 0.04), and with significant increased MIC50 values for amphotericin B (p = 0.01) over the study period. In conclusion, drug utilization in our hospital turned out to be a putative influencing factor on the ecology of the species, on the increase in time of the biofilm producing strains and on the Candida antifungal susceptibility profile, thus influencing clinical management.
year | journal | country | edition | language |
---|---|---|---|---|
2019-01-01 | PLOS ONE |